This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Lifshitz Law Firm Announces Class Action Lawsuits Against Affymax, Inc., Impax Laboratories Inc., And Tangoe, Inc.

Stocks in this article: AFFYIPXLTNGO

NEW YORK, March 18, 2013 /PRNewswire/ --

Affymax, Inc.

Lifshitz Law Firm announces that a class action suit was filed in the United States District Court for the Northern District of California, alleging that Affymax, Inc. ("Affymax" or the "Company") (AFFY) issued false and misleading statements to investors between December 8, 2011 and February 22, 2013 (the "Class Period") by failing to adequately disclose: (1) that the Company's FY 2012 financial guidance was materially overstated; (2) that reported sales of its primary drug product were not sustainable; and (3) that the defendants were materially overstating sales and understating the potential liabilities related to its primary drug product, including refunds and potential liability to injured patients.

For more information, please contact Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Impax Laboratories Inc.

Lifshitz Law Firm announces that a class action suit was filed in the United States District Court for the Northern District of California on behalf of purchasers of Impax Laboratories Inc. ("Impax" or the "Company") (IPXL) between June 6, 2011 through March 4, 2013, inclusive (the "Class Period").  The Complaint alleges defendants misrepresented and/or failed to disclose that at its Hayward facility: (1) the Company failed to maintain proper quality control and manufacturing practices in violation of current GMP; (2) the Company failed to take proper remedial actions to correct quality control issues previously identified by the FDA in prior inspections; and (3) the Company failed to disclose the extent of the adverse impact the manufacturing deficiencies could have on the Company's ability to successfully launch its new drug, Rytary.

For more information, please contact Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Tangoe, Inc.

Lifshitz Law Firm announces that a class action suit was filed in the United States District Court for the District of Connecticut on behalf of all persons or entities who purchased Tangoe, Inc. ("Tangoe" or the "Company") (TNGO) securities between December 20, 2011 and September 5, 2012 (the "Class Period").  The Complaint alleges defendants misrepresented and/or failed to disclose that (1) the Company was overstating organic growth by underreporting the percentage of revenue derived from recent acquisitions; (2) the Company was not growing customers organically as its deferred implementation fees failed to grow; and (3) as a result of the above, the Company's financial statements were materially false and misleading at all relevant times.

For more information, please contact Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Lifshitz Law Firm is a New York based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions.  For more information about the firm, please visit our website at www.jlclasslaw.com.

ATTORNEY ADVERTISING . © 2013 Lifshitz Law Firm.  The law firm responsible for this advertisement is Lifshitz Law Firm, 18 East 41 st Street, New York, New York 10017, (212) 213-6222.  Prior results do not guarantee or predict a similar outcome with respect to any future matter .

Contact: 

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs